These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16115187)

  • 21. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
    Chiang SS; Chen JB; Yang WC
    Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
    Spasovski GB; Sikole A; Gelev S; Masin-Spasovska J; Freemont T; Webster I; Gill M; Jones C; De Broe ME; D'Haese PC
    Nephrol Dial Transplant; 2006 Aug; 21(8):2217-24. PubMed ID: 16595583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
    Finn WF; Joy MS; Hladik G;
    Clin Nephrol; 2004 Sep; 62(3):193-201. PubMed ID: 15481851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
    Freemont AJ; Hoyland JA; Denton J;
    Clin Nephrol; 2005 Dec; 64(6):428-37. PubMed ID: 16370155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
    Cozzolino M; Brancaccio D
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):29-34. PubMed ID: 18221100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.
    Cozzolino M; Brancaccio D
    Expert Opin Emerg Drugs; 2007 Sep; 12(3):341-3. PubMed ID: 17874964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
    Lorenzo Sellares V; Torres Ramírez A
    Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blast from the past: the aluminum's ghost on the lanthanum salts.
    Canavese C; Mereu C; Nordio M; Sabbioni E; Aime S
    Curr Med Chem; 2005; 12(14):1631-6. PubMed ID: 16022663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.
    Neven E; Dams G; Postnov A; Chen B; De Clerck N; De Broe ME; D'Haese PC; Persy V
    Nephrol Dial Transplant; 2009 Jun; 24(6):1790-9. PubMed ID: 19144999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
    Al-Baaj F; Speake M; Hutchison AJ
    Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperphosphataemia in renal failure: causes, consequences and current management.
    Albaaj F; Hutchison A
    Drugs; 2003; 63(6):577-96. PubMed ID: 12656655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lanthanum carbonate--new data on parathyroid hormone control without liver damage.
    Cozzolino M; Brancaccio D
    Nephrol Dial Transplant; 2007 Feb; 22(2):316-8. PubMed ID: 17151005
    [No Abstract]   [Full Text] [Related]  

  • 35. Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.
    Curran MP; Robinson DM
    Drugs; 2009 Nov; 69(16):2329-49. PubMed ID: 19852531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
    Negi S; Shigematsu T
    Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
    Altmann P; Barnett ME; Finn WF;
    Kidney Int; 2007 Feb; 71(3):252-9. PubMed ID: 17035945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lanthanum: a safe phosphate binder.
    Persy VP; Behets GJ; Bervoets AR; De Broe ME; D'Haese PC
    Semin Dial; 2006; 19(3):195-9. PubMed ID: 16689967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical management of hyperphosphatemia.
    Ritz E
    J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of lanthanum carbonate in German patients on dialysis.
    Dellanna F; Reichel H; Seibt F
    Clin Nephrol; 2012 Nov; 78(5):382-90. PubMed ID: 22948119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.